Last Updated : May 3, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name Sort descending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Zenhale | Mometasone/formoterol | Asthma | List with clinical criteria and/or conditions | Complete | ||
| Myfortic | Mycophenolate sodium | Organ rejection in allogeneic renal transplants, Prophylaxis | List in a similar manner to other drugs in class | Complete | ||
| N/A | Nab-paclitaxel | Solid tumours | Active | |||
| N/A | Nab-paclitaxel | Gastrointestinal cancer | Active | |||
| Abraxane | Nab-paclitaxel | Metastatic Pancreatic Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| N/A | nab-paclitaxel | Gastrointestinal cancer | Pending | |||
| Contrave | naltrexone hydrochloride and bupropion hydrochloride | Chronic weight management in adults | Do not reimburse | Complete | ||
| Onivyde | Nanoliposomal Irinotecan | Cancelled | ||||
| Tysabri | natalizumab | Multiple Sclerosis, relapsing-remitting | Withdrawn | |||
| Tysabri | Natalizumab | Multiple Sclerosis, relapsing-remitting | List with clinical criteria and/or conditions | Complete |
Last Updated : May 3, 2024